Inhibition of Jurkat T cell growth by most active compounds selected from the initial screening.

Compound		Ar	GI50a ± SEMb (μM)
9{2,12}		4-CF3OC6H4	10.81 ± 0.13
9{2,13}		3-PhOC6H4	6.88 ± 1.22
9{2,14}		3-BnOC6H4	7.68 ± 0.11
9{3,11}		4-CF3C6H4	4.51 ± 0.15
9{3,12}		4-CF3OC6H4	3.23 ± 0.88
9{3,18}		2-Thienyl	28.17 ± 1.03
9{4,7}		4-tBuC6H4	21.83 ± 1.10
9{6,1}		Ph	1.95 ± 0.25
9{6,2}		3-FC6H4	1.02 ± 0.30
9{6,4}		4-ClC6H4	3.30 ± 0.65
9{6,5}		3-MeC6H4	1.14 ± 0.13
9{6,6}		4-MeC6H4	1.79 ± 0.58
9{6,7}		4-tBuC6H4	2.43 ± 0.57
9{6,9}		4-MeOC6H4	29.59 ± 2.20
9{6,11}		4-CF3C6H4	3.23 ± 0.16
9{6,12}		4-CF3OC6H4	1.18 ± 0.22
9{6,13}		3-PhOC6H4	1.54 ± 0.66
9{6,14}		3-BnOC6H4	6.54 ± 0.34
9{6,16}		3,4-MeOC6H3	11.64 ± 2.12
9{7,3}		4-FC6H4	1.89 ± 0.48
9{7,8}		4-Me2NC6H4	2.12 ± 0.97
9{7,15}		4-BnOC6H4	23.07 ± 0.08
9{7,17}		3,4,5-MeOC6H2	6.73 ± 0.43
9{7,18}		2-Thienyl	6.03 ± 0.64
Mercaptopurinec	—	—	11.12 ± 4.89
Methotrexatec	—	—	0.37 ± 0.03
Cytarabinec	—	—	0.29 ± 0.01

^aConcentration (μM) required to inhibit Jurkat T cell growth by 50%, values are the mean of three independent experiments.

^bStandard error of the mean.

^cPositive controls.